keyword
https://read.qxmd.com/read/32747907/is-there-a-relationship-in-between-ovarian-endometriosis-and-ovarian-cancer-immunohistochemical-profile-of-four-cases-with-coexisting-ovarian-endometriosis-and-cancer
#1
Roxana Cleopatra Penciu, Iulia Postolache, Liliana Steriu, Silvia Izvoranu, Andrei Adrian Tica, Iulia Diana Mocanu, Vasile Sârbu, Mariana Deacu, Irina Tica, Gabriela Izabela Bălţătescu, Oana Sorina Tica, Vlad Iustin Tica
Endometriosis (EMs) is a benign disease characterized by the presence of endometrial tissue outside the uterine cavity. EMs associated with ovarian cancer (OC) has a relative low incidence (5% to 10%), sometimes with evidence of a transition stage through atypical EMs (1.6% cases). We have assessed 135 consecutive patients with either EMs or OC and, out of them, our study reports on four cases of ovarian EMs and OC: two cases with endometrioid OC and two cases with high-grade serous OC (HGSOC). Cases with EMs and HGSOC are extremely rarely reported in the literature - we could find not more than 30 cases...
2020: Romanian Journal of Morphology and Embryology
https://read.qxmd.com/read/32727341/cognitive-functions-under-anti-her2-targeted-therapy-in-cancer-patients-a-scoping-review
#2
Javier García-Sánchez, María D Torregrosa, Omar Cauli
BACKGROUND AND OBJECTIVE: Pharmacological therapy targeting the HER2 protein is one of the major breakthroughs in the treatment of cancer patients overexpressing HER2 who have increased survival rates. Despite improved survival, it is important to determine the less frequent adverse effects in order to tailor treatments more personalized to the patients' features. The possible impact of cancer treatments on cognitive functions is huge, and the effects of anti-HER 2 therapies on this issue have not been reviewed and are the objective of this study...
July 29, 2020: Endocrine, Metabolic & Immune Disorders Drug Targets
https://read.qxmd.com/read/32675056/adjuvant-treatment-for-patients-with-figo-stage-i-uterine-serous-carcinoma-confined-to-the-endometrium
#3
Dimitrios Nasioudis, Allison Grace Roy, Emily M Ko, Lori Cory, Robert L Giuntoli Ii, Ashley F Haggerty, Sarah H Kim, Mark A Morgan, Nawar A Latif
OBJECTIVES: The role of adjuvant treatment for early-stage uterine serous carcinoma is not defined. The goal of this study was to investigate the impact of adjuvant treatment on survival of patients with tumors confined to the endometrium. METHODS: Patients diagnosed with stage I uterine serous carcinoma with no myometrial invasion between January 2004 and December 2015 who underwent hysterectomy with at least 10 lymph nodes removed were identified from the National Cancer Database...
July 15, 2020: International Journal of Gynecological Cancer
https://read.qxmd.com/read/32601075/randomized-phase-ii-trial-of-carboplatin-paclitaxel-compared-with-carboplatin-paclitaxel-trastuzumab-in-advanced-stage-iii-iv-or-recurrent-uterine-serous-carcinomas-that-overexpress-her2-neu-nct01367002-updated-overall-survival-analysis
#4
Amanda N Fader, Dana M Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M O'Malley, Floor J Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E Schwartz, Alessandro D Santin
PURPOSE: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P), is recognized as an alternative in treating advanced/recurrent HER2/Neu-positive USC. We report the updated survival analysis of NCT01367002. PATIENTS AND METHODS: Eligible patients had stage III to IV or recurrent disease...
June 29, 2020: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://read.qxmd.com/read/32536817/comprehensive-analysis-of-ldhap5-pseudogene-expression-and-potential-pathogenesis-in-ovarian-serous-cystadenocarcinoma
#5
Shitong Lin, Yifan Meng, Canhui Cao, Ping Wu, Peipei Gao, Wenhua Zhi, Ting Peng, Peng Wu
Background: We aimed to identify differentially expressed pseudogenes and explore their potential functions in four types of common gynecological malignancies (e.g., cervical squamous cell carcinoma, ovarian serous cystadenocarcinoma, uterine corpus endometrial carcinoma, and uterine carcinosarcoma) using bioinformatics technology. Materials and methods: We identified up-regulated and down-regulated pseudogenes and built a pseudogene-miRNA-mRNA regulatory network through public datasets to explore their potential functions in carcinogenesis and cancer prognosis...
2020: Cancer Cell International
https://read.qxmd.com/read/32531179/the-current-clinical-approach-to-newly-diagnosed-uterine-cancer
#6
Olga T Filippova, Mario M Leitao
INTRODUCTION: Uterine cancer is the most common gynecologic malignancy, although fortunately, 75% of women present with early-stage disease. A major area of controversy regarding the management of the disease concerns postoperative therapy for both women with early- and advanced-stage endometrial carcinoma. Here, we review landmark evidence that can help guide clinical decision-making in the treatment of women diagnosed with endometrial cancer. AREAS COVERED: In this review, we present the latest data driving decisions for both surgical management and postoperative therapy for women with endometrial carcinoma...
June 22, 2020: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/32514162/low-junctional-adhesion-molecule-a-expression-is-associated-with-an-epithelial-to-mesenchymal-transition-and-poorer-outcomes-in-high-grade-serous-carcinoma-of-uterine-adnexa
#7
Laudine Communal, Mauricio Medrano, Fabrice Sircoulomb, Joshua Paterson, Martin Köbel, Kurosh Rahimi, Paul Hoskins, Dongsheng Tu, Stephanie Lheureux, Amit Oza, Laurie Ailles, Diane Provencher, Robert Rottapel, Anne-Marie Mes-Masson
High-grade serous carcinoma of uterine adnexa (HGSC) is the most frequent histotype of epithelial ovarian cancer and has a poor 5-year survival rate due to late-stage diagnosis and the poor efficacy of standard treatments. Novel biomarkers of cancer outcome are needed to identify new targetable pathways and improve personalized treatments. Cell-surface screening of 26 HGSC cell lines by high-throughput flow cytometry identified junctional adhesion molecule 1 (JAM-A, also known as F11R) as a potential biomarker...
June 8, 2020: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://read.qxmd.com/read/32507853/oestrogen-receptor-pathway-activity-is-associated-with-outcome-in-endometrial-cancer
#8
Willem Jan van Weelden, Louis J M van der Putten, Márcia A Inda, Anne van Brussel, Marc P L M Snijders, Lisanne M M Schriever, Johan Bulten, Leon F A G Massuger, Anja van de Stolpe, Johanna M A Pijnenborg
BACKGROUND: Oestrogen receptor (ER) expression is a prognostic biomarker in endometrial cancer (EC). However, expression does not provide information about the functional activity of the ER pathway. We evaluated a model to quantify ER pathway activity in EC, and determined the prognostic relevance of ER pathway activity. METHODS: ER pathway activity was measured in two publicly available datasets with endometrial and EC tissue, and one clinical cohort with 107 samples from proliferative and hyperplastic endometrium and endometrioid-type EC (EEC) and uterine serous cancer (USC)...
June 8, 2020: British Journal of Cancer
https://read.qxmd.com/read/32471518/ancestry-specific-predisposing-germline-variants-in-cancer
#9
Ninad Oak, Andrew D Cherniack, R Jay Mashl, Fred R Hirsch, Li Ding, Rameen Beroukhim, Zeynep H Gümüş, Sharon E Plon, Kuan-Lin Huang
BACKGROUND: Distinct prevalence of inherited genetic predisposition may partially explain the difference of cancer risks across ancestries. Ancestry-specific analyses of germline genomes are required to inform cancer genetic risk and prognosis of diverse populations. METHODS: We conducted analyses using germline and somatic sequencing data generated by The Cancer Genome Atlas. Collapsing pathogenic and likely pathogenic variants to cancer predisposition genes (CPG), we analyzed the association between CPGs and cancer types within ancestral groups...
May 29, 2020: Genome Medicine
https://read.qxmd.com/read/32454416/impact-of-different-adjuvant-treatment-approaches-on-survival-in-stage-iii-endometrial-cancer-a-population-based-study
#10
Willem Jan van Weelden, Casper Reijnen, Florine A Eggink, Dorry Boll, Petronella B Ottevanger, Hetty A van den Berg, Maaike A van der Aa, Johanna M A Pijnenborg
BACKGROUND: Patients with International Federation of Gynaecology and Obstetrics (FIGO) stage III endometrial cancer (EC) have a substantial risk of adverse outcomes. After surgery, adjuvant therapy is recommended with external beam radiotherapy (EBRT), chemotherapy (CT) or both EBRT and CT. Recent trials suggest that EBRT + CT is superior to EBRT or CT alone but also results in more toxicity. We have compared the outcome of different adjuvant treatments in a population-based cohort to identify subgroups that benefit most from EBRT + CT...
July 2020: European Journal of Cancer
https://read.qxmd.com/read/32402510/comprehensive-lymphadenectomy-and-survival-prediction-in-uterine-serous-cancer-patients-after-surgery-a-population-based-analysis
#11
Hui Li, Xiaofei Xie, Yunyun Liu, Xiaoxin Huang, Haoliang Lin, Jing Li, Zhongqiu Lin
OBJECTIVE: Evidence on uterine serous cancer (USC) prognosis has been limited and inconclusive. We aim to explore the survival benefits of comprehensive lymphadenectomy in USC patients after surgery and develop a prognostic nomogram to predict survival. METHODS: USC patients who had undergone hysterectomy between 2010 and 2015 were identified from Surveillance, Epidemiology and End Results (SEER) database. The relationship between the extent of lymphadenectomy and survival, including overall survival (OS) and cancer-specific survival (CSS), was estimated with Kaplan-Meier (K-M) analysis...
July 2020: European Journal of Surgical Oncology
https://read.qxmd.com/read/32258332/human-epidermal-growth-factor-receptor-2-her2-testing-for-uterine-serous-carcinoma-report-of-scenarios-of-unusual-overexpression
#12
M Ruhul Quddus, Katrine Hansen, Umadevi Tantravahi, C James Sung
The human epidermal growth factor receptor 2 (Her2) is tested in many human cancers, including breast, bladder, pancreatic, ovarian and stomach. The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) have issued Clinical Practice Guidelines for reporting Her2 results for breast carcinomas (Wolf et al., 2018). For the last 1-2 years Her2/neu is tested in endometrial serous carcinoma, especially in recurrent tumors or non-responsive tumors as an option for additional treatment...
May 2020: Gynecologic Oncology Reports
https://read.qxmd.com/read/32227579/a-comprehensive-analysis-of-ido1-expression-with-tumour-infiltrating-immune-cells-and-mutation-burden-in-gynaecologic-and-breast-cancers
#13
Xu Feng, Ranran Tang, Runjie Zhang, Huan Wang, Zhaodong Ji, Yang Shao, Shuoer Wang, Tianying Zhong, Yun Gu, Jiao Meng
Gynaecologic and breast cancers share some similarities at the molecular level. The aims of our study are to highlight the similarities and differences about IDO1, an important immune-related gene in female cancers. The NGS data from TCGA of cervical squamous cell carcinoma (CESC), ovarian serous cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS) and breast invasive carcinoma (BRCA) were analysed to identify molecular features, and clinically significant and potential therapeutic targets of IDO1...
March 30, 2020: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/32200352/comparison-of-lymphoscintigraphy-and-single-photon-emission-computed-tomography-with-computed-tomography-spect-ct-for-sentinel-lymph-node-detection-in-endometrial-cancer
#14
Shinichi Togami, Toshihiko Kawamura, Shintaro Yanazume, Masaki Kamio, Hiroaki Kobayashi
BACKGROUND: Endometrial cancer is the most common gynecologic cancer, and lymph node metastasis is one of the most important prognostic factors. Increasing evidence shows that sentinel lymph node (SLN) mapping is an effective alternative to comprehensive lymphadenectomy. Single photon emission CT with computed tomography (SPECT/CT) is associated with a high SLN detection rate. OBJECTIVE: To compare the clinical efficacy of SPECT/CT with that of lymphoscintigraphy in detecting SLNs in patients with endometrial cancer...
March 21, 2020: International Journal of Gynecological Cancer
https://read.qxmd.com/read/32190072/the-role-of-vaginal-brachytherapy-in-stage-i-endometrial-serous-cancer-a-systematic-review
#15
REVIEW
Valentina Lancellotta, Francesca De Felice, Lisa Vicenzi, Alfredo Antonacci, Valentina Cerboneschi, Sara Costantini, Daniela di Cristino, Luca Tagliaferri, Annamaria Cerrotta, Andrea Vavassori, Sergio Gribaudo, Alessandro Colombo, Francesco Lucà, Raffaele Barbara, Monica Mangoni, Francesco Marampon, Daniela Musio, Filippo Bellati, Francesco Torcia, Vincenzo Tombolini, Mattia Falchetto Osti, Vitaliana De Sanctis
Purpose: Serous adenocarcinoma (uterine serous carcinoma - USC) is a rare and aggressive histologic subtype of endometrial cancer, with a high-rate of recurrence and poor prognosis. The adjuvant treatment for stage I patients is unclear. The purpose of this study was to evaluate the outcomes of stage I USC treated exclusively with chemotherapy plus vaginal brachytherapy (VBT). Material and methods: A systematic research using PubMed, Scopus, and Cochrane library was conducted to identify full articles evaluating the efficacy of VBT in patients with stage I USC...
February 2020: Journal of Contemporary Brachytherapy
https://read.qxmd.com/read/32183290/pathogenesis-and-clinical-management-of-uterine-serous-carcinoma
#16
REVIEW
Li Zhang, Suet Ying Kwan, Kwong Kwok Wong, Pamela T Solaman, Karen H Lu, Samuel C Mok
Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer that has not been well characterized. It accounts for less than 10% of all endometrial cancers and 80% of endometrial cancer-related deaths. Currently, staging surgery together with chemotherapy or radiotherapy, especially vaginal cuff brachytherapy, is the main treatment strategy for USC. Whole-exome sequencing combined with preclinical and clinical studies are verifying a series of effective and clinically accessible inhibitors targeting frequently altered genes, such as HER2 and PI3K3CA , in varying USC patient populations...
March 14, 2020: Cancers
https://read.qxmd.com/read/32182501/fertility-preserving-surgery-for-high-grade-epithelial-ovarian-carcinoma-confined-to-the-ovary
#17
Dimitrios Nasioudis, Spyridon A Mastroyannis, Ashley F Haggerty, Robert L Giuntoli, Mark A Morgan, Emily M Ko, Nawar A Latif
OBJECTIVE: To investigate the safety of uterine preservation in patients with high-grade epithelial ovarian carcinoma (EOC). STUDY DESIGN: The Surveillance, Epidemiology, and End Results database was accessed (1988-2014) and patients aged < = 45 years, diagnosed with an unilateral high-grade non-clear cell EOC confined to the ovary were selected. Based on surgery codes we determined whether hysterectomy was performed. Overall (OS) and cancer-specific survival (CSS) was estimated calculated following generation of Kaplan-Meier curves and compared using the log-rank test...
January 30, 2020: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://read.qxmd.com/read/32140533/selection-of-her2-neu-negative-tumor-cells-as-a-mechanism-of-resistance-to-trastuzumab-in-uterine-serous-carcinoma
#18
Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E Schwartz, Giovanni Scambia, Alessandro D Santin
Background: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment of advanced or recurrent HER2/Neu+ USC per NCCN guidelines. Case: We describe two USC patients with overexpression of HER2/neu at 2+/3+ level by immunohistochemistry and c-erbB2 gene amplification by fluorescence in situ hybridization (FISH) assay that, after an initial clinical response to trastuzumab, developed resistance/progression...
May 2020: Gynecologic Oncology Reports
https://read.qxmd.com/read/32139151/an-integrated-molecular-profile-of-endometrioid-ovarian-cancer
#19
William E Pierson, Pamela N Peters, Matthew T Chang, Lee-May Chen, David A Quigley, Alan Ashworth, Jocelyn S Chapman
OBJECTIVE: Endometrioid ovarian carcinoma (EOVC) is an uncommon subtype of epithelial ovarian carcinoma and its molecular characteristics have been incompletely described. Prior sequencing investigations have been limited to targeted gene panels. We performed whole-exome sequencing to build an unbiased genetic profile of molecular alterations in endometrioid ovarian tumors with a goal to better understand this disease in the context of epithelial ovarian cancer and endometrioid uterine cancers...
March 2, 2020: Gynecologic Oncology
https://read.qxmd.com/read/32120796/non-surgical-cancer-risk-reduction-in-brca1-mutation-carriers-disabling-the-remote-control
#20
Martin Widschwendter, Louis Dubeau
Women-specific cancers are a major health issue, particularly those associated with the BRCA 1 germline mutation carrier state, which include triple-negative basal breast carcinomas and high-grade serous ovarian carcinomas (referred to as extra-uterine Müllerian carcinomas). Whereas many chronic diseases can currently be prevented (e.g., cardiovascular diseases), no recent tangible progress was made in cancer prevention of BRCA1 mutation carriers apart from surgical resections of at-risk organs. This lack of progress is largely due to (1) poor understanding of the initiating events triggered by known risk factors in the development of these cancers, (2) the fact that current preventive measures rely on evidence obtained from adjuvant breast cancer treatment that fail to protect against poor prognostic cancers, and (3) problems with using cancer incidence in high-risk women as an ethically justifiable endpoint in cancer prevention trials...
February 27, 2020: Cancers
keyword
keyword
16962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"